Abstract

Tumor cells may express on their surface various characteristic antigens that can induce antitumor immunity. However, cancer in human body may induce an immunosuppressive microenvironment that limits immune response to its antigens. For many years scientists have tried to develop an immunotherapy which would induce a potent antitumor immune response and lead to an elimination of the disease. One of the most promising immunotherapies is blockade of immune checkpoints, i.e. a group of costimulatory molecules negatively regulating the immune system. Their blockade would overcome immune tolerance in the tumor microenvironment and amplify antitumor immunity. What’s more, immune checkpoint blockade may turn out even more profitable, as some of immune checkpoints and their ligands are expressed on tumor surface and on tumor infiltrating lymphocytes, contributing to the immunosuppressive cancer microenvironment. Phase III clinical trials have confirmed efficacy of an anti‑CTLA‑4 antibody ipilimumab, thereby leading to its acceptance for the treatment of advanced melanoma. Thanks to promising results of the phase I clinical trials, a breakthrough therapy designation and an early approval for the treatment have been granted to anti‑PD‑1 antibodies ‑ nivolumab (for the treatment of advanced melanoma and advanced non‑small cell lung cancer) and pembrolizumab (for the treatment of advanced melanoma) and, in the treatment of advanced bladder cancer, an anti‑PD‑L1 antibody ‑ MPDL3280A as well. Other immune checkpoints, such as LAG‑3, TIM‑3, BTLA, B7‑H3 and B7‑H4, are also under early evaluation.

References

• 1. Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C.,Gutierrez M., Schuster S.J., Millenson M.M., Cattry D., Freeman G.J.,Rodig S.J., Chapuy B., Ligon A.H., Zhu L., Grosso J.F. i wsp.: PD-1 blockadewith nivolumab in relapsed or refractory Hodgkin’s lymphoma.N. Engl. J. Med., 2015; 372: 311-319
  Google Scholar
• 2. Berman D., Parker S.M., Siegel J., Chasalow S.D., Weber J., GalbraithS., Targan S.R., Wang H.L.: Blockade of cytotoxic T-lymphocyteantigen-4 by ipilimumab results in deregulation of gastrointestinalimmunity in patients with advanced melanoma. Cancer Immun.,2010; 10: 11
  Google Scholar
• 3. Berrien-Elliott M.M., Jackson S.R., Meyer J.M., Rouskey C.J., NguyenT.L., Yagita H., Greenberg P.D., DiPaolo R.J., Teague R.M.: Durableadoptive immunotherapy for leukemia produced by manipulationof multiple regulatory pathways of CD8+ T-cell tolerance. CancerRes., 2013; 73: 605-616 4 Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., SharfmanW.H., Stankevich E., Pons A., Salay T.M., McMiller T.L., GilsonM.M., Wang C., Selby M., Taube J.M., Anders R. i wsp.: Phase I studyof single-agent anti-programmed death-1 (MDX-1106) in refractorysolid tumors: safety, clinical activity, pharmacodynamics, and immunologiccorrelates. J. Clin. Oncol., 2010; 28: 3167-3175
  Google Scholar
• 4. blockade in preclinical tumor models. Cancer Immunol. Immunother.,2013; 62: 1533-1545
  Google Scholar
• 5. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., HwuP., Drake C.G., Camacho L.H., Kauh J., Odunsi K., Pitot H.C., HamidO., Bhatia S., Martins R., Eaton K. i wsp.: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med.,2012; 366: 2455-2465
  Google Scholar
• 6. Bronstein Y., Ng C.S., Hwu P., Hwu W.J.: Radiologic manifestationsof immune-related adverse events in patients with metastatic melanomaundergoing anti-CTLA-4 antibody therapy. Am. J. Roentgenol.,2011; 197: W992-W1000
  Google Scholar
• 7. Cao Y., Zhou X., Huang X., Li Q., Gao L., Jiang L., Huang M., ZhouJ.: Tim-3 expression in cervical cancer promotes tumor metastasis.PLoS One, 2013; 8: e53834
  Google Scholar
• 8. Chapman P.B., D’Angelo S.P., Wolchok J.D.: Rapid eradication ofa bulky melanoma mass with one dose of immunotherapy. N. Eng.J. Med., 2015; 372: 2073-2074
  Google Scholar
• 9. Chen L.: Co-inhibitory molecules of the B7-CD28 family in thecontrol of T-cell immunity. Nat. Rev. Immunol., 2004; 4: 336-347
  Google Scholar
• 10. Chen L., Flies D.B.: Molecular mechanisms of T cell co-stimulationand co-inhibition. Nat. Rev. Immunol., 2013; 13: 227-242
  Google Scholar
• 11. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/home(29.12.2014)
  Google Scholar
• 12. Dangaj D., Lanitis E., Zhao A., Joshi S., Cheng Y., SandaltzopoulosR., Ra H.J., Danet-Desnoyers G., Powell D.J.Jr, Scholler N.: Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res., 2013;73: 4820-4829
  Google Scholar
• 13. Drake C.G., Lipson E.J., Brahmer J.R.: Breathing new life intoimmunotherapy: review of melanoma, lung and kidney cancer. Nat.Rev. Clin. Oncol., 2014; 11: 24-37
  Google Scholar
• 14. Fauci J.M., Sabbatino F., Wang Y., Londoño-Joshi A.I., StraughnJ.M.Jr., Landen C.N., Ferrone S., Buchsbaum D.J.: Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovariancancer cells with the B7-H3-specific mAb 376.96. Gynecol. Oncol.,2014; 132: 203-210
  Google Scholar
• 15. Fife B.T., Pauken K.E., Eagar T.N., Obu T., Wu J., Tang Q., AzumaM., Krummel M.F., Bluestone J.A.: Interactions between PD-1 andPD-L1 promote tolerance by blocking the TCR-induced stop signal.Nat. Immunol., 2009; 10: 1185-1192
  Google Scholar
• 16. Fourcade J., Sun Z., Pagliano O., Guillaume P., Luescher I.F., SanderC., Kirkwood J.M., Olive D., Kuchroo V., Zarour H.M.: CD8+ T cellsspecific for tumor antigens can be rendered dysfunctional by thetumor microenvironment through upregulation of the inhibitoryreceptors BTLA and PD-1. Cancer Res., 2012; 72: 887-896
  Google Scholar
• 17. Francisco L.M., Sage P.T., Sharpe A.H.: The PD-1 pathway in toleranceand autoimmunity. Immunol. Rev., 2010; 236: 219-242
  Google Scholar
• 18. Garon E.B., Rizvi N.A., Hui R., Leighl N., Balmanoukian A.S., EderJ.P., Patnaik A., Aggarwal C., Gubens M., Horn L., Carcereny E., AhnM.J., Felip E., Lee J.S., Hellmann M.D. i wsp.: Pembrolizumab for thetreatment of non-small-cell lung cancer. N. Eng. J. Med., 2015; 372:2018-2028
  Google Scholar
• 19. Gettinger S.N., Horn L., Gandhi L., Spigel D.R., Antonia S.J., RizviN.A., Powderly J.D., Heist R.S., Carvajal R.D., Jackman D.M., SequistL.V., Smith D.C., Leming P., Carbone D.P., Pinder-Schenck M.C.i wsp.: Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patientswith previously treated advanced non–small-cell lung cancer. J. Clin.Oncol., 2015; 33: 2004-2012
  Google Scholar
• 20. Goldberg M.V., Drake C.G.: LAG-3 in cancer immunotherapy.Curr. Top. Microbiol. Immunol., 2011; 344: 269-278
  Google Scholar
• 21. Grosso J.F., Jure-Kunkel M.N.: CTLA-4 blockade in tumor models:an overview of preclinical and translational research. CancerImmun., 2013; 13: 5-18
  Google Scholar
• 22. Grosso J.F., Kelleher C.C., Harris T.J., Maris C.H., Hipkiss E.L., DeMarzo A., Anders R., Netto G., Getnet D., Bruno T.C., Goldberg M.V.,Pardoll D.M., Drake C.G.: LAG-3 regulates CD8+ T cell accumulationand effector function in murine self – and tumor-tolerance systems.J. Clin. Invest., 2007; 117: 3383-3392
  Google Scholar
• 23. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R.,Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., Dronca R., GangadharT.C., Patnaik A., Zarour H., Joshua A.M. i wsp.: Safety and tumorresponses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J.Med., 2013; 369: 134-144
  Google Scholar
• 24. Hodi F.S., Lawrence D., Lezcano C., Wu X., Zhou J., Sasada T.,Zeng W., Giobbie-Hurder A., Atkins M.B., Ibrahim N., FriedlanderP., Flaherty K.T., Murphy G.F., Rodig S., Velazquez E.F. i wsp.: Bevacizumabplus ipilimumab in patients with metastatic melanoma.Cancer Immunol. Res., 2014; 2: 632-642
  Google Scholar
• 25. Hodi F.S., O’Day S.J., McDermott D.F., Weber R.W., Sosman J.A.,Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., AkerleyW., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M.i wsp.: Improved survival with ipilimumab in patients with metastaticmelanoma. N. Engl. J. Med., 2010; 363: 711-723
  Google Scholar
• 26. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N.: Involvementof PD-L1 on tumor cells in the escape from host immunesystem and tumor immunotherapy by PD-L1 blockade. Proc. Natl.Acad. Sci. USA, 2002; 99: 12293-12297
  Google Scholar
• 27. Jure-Kunkel M., Masters G., Girit E., Dito G., Lee F., Hunt J.T.,Humphrey R.: Synergy between chemotherapeutic agents and CTLA-
  Google Scholar
• 28. Karim R., Jordanova E.S., Piersma S.J., Kenter G.G., Chen L., BoerJ.M., Melief C.J., van der Burg S.H.: Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patientswith cervical carcinoma. Clin. Cancer. Res., 2009; 15: 6341-6347
  Google Scholar
• 29. Keir M.E., Francisco L.M., Sharpe A.H.: PD-1 and its ligands inT-cell immunity. Curr. Opin. Immunol., 2007; 19: 309-314
  Google Scholar
• 30. Korman A.J., Peggs K.S., Allison J.P.: Checkpoint blockade in cancerimmunotherapy. Adv. Immunol., 2006; 90: 297-339
  Google Scholar
• 31. Kvistborg P., Philips D., Kelderman S., Hageman L., OttensmeierC., Joseph-Pietras D., Welters M.J., van der Burg S., Kapiteijn E., MichielinO., Romano E., Linnemann C., Speiser D., Blank C., Haanen J.B.,Schumacher T.N.: Anti-CTLA-4 therapy broadens the melanomareactiveCD8+ T cell response. Sci. Transl. Med., 2014; 6: 254ra128
  Google Scholar
• 32. Kyi C., Hellmann M.D., Wolchok J.D., Chapman P.B., Postow M.A..:Opportunistic infections in patients treated with immunotherapyfor cancer. J. Immunother. Cancer, 2014; 2: 19
  Google Scholar
• 33. Leach D.R., Krummel M.F., Allison J.P.: Enhancement of antitumorimmunity by CTLA-4 blockade. Science, 1996; 271: 1734-1736
  Google Scholar
• 34. Lebbé C., Weber J.S., Maio M., Neyns B., Harmankaya K., HamidO., O’Day S.J., Konto C., Cykowski L., McHenry M.B., Wolchok J.D.:Survival follow-up and ipilimumab retreatment of patients withadvanced melanoma who received ipilimumab in prior phase IIstudies. Ann. Oncol., 2014; 25: 2277-2284
  Google Scholar
• 35. Lesterhuis W.J., Salmons J., Nowak A.K., Rozali E.N., Khong A.,Dick I.M., Harken J.A., Robinson B.W., Lake R.A.: Synergistic effectof CTLA-4 blockade and cancer chemotherapy in the induction ofanti-tumor immunity. PLoS One, 2013; 8: e61895
  Google Scholar
• 36. Lipson E.J., Sharfman W.H., Drake C.G., Wollner I., Taube J.M.,Anders R.A., Xu H., Yao S., Pons A., Chen L., Pardoll D.M., BrahmerJ.R., Topalian S.L.: Durable cancer regression off-treatment and effectivereinduction therapy with an anti-PD-1 antibody. Clin. CancerRes., 2013; 19: 462-468
  Google Scholar
• 37. Liu W., Shibata K., Koya Y., Kajiyama H., Senga T., Yamashita M.,Kikkawa F.: B7-H4 overexpression correlates with a poor prognosisfor cervical cancer patients. Mol. Clin. Oncol., 2014; 2: 219-225
  Google Scholar
• 38. Markstein M., Dettorre S., Cho J., Neumüller R.A., Craig-Müller S.,Perrimon N.: Systematic screen of chemotherapeutics in Drosophilastem cell tumors. Proc. Natl. Acad. Sci. USA, 2014; 111: 4530-4535
  Google Scholar
• 39. McDermott D., Haanen J., Chen T.T., Lorigan P., O’Day S.: Efficacyand safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann. Oncol., 2013; 24: 2694-2698
  Google Scholar
• 40. McDermott D., Lebbé C., Hodi F.S., Maio M., Weber J.S., WolchokJ.D., Thompson J.A., Balch C.M.: Durable benefit and the potentialfor long-term survival with immunotherapy in advanced melanoma.Cancer Treat. Rev., 2014; 40: 1056-1064
  Google Scholar
• 41. Mkrtichyan M., Najjar Y.G., Raulfs E.C., Abdalla M.Y., SamaraR., Rotem-Yehudar R., Cook L., Khleif S.N.: Anti-PD-1 synergizeswith cyclophosphamide to induce potent anti-tumor vaccine effectsthrough novel mechanisms. Eur. J. Immunol., 2011; 41: 2977-2986
  Google Scholar
• 42. Muenst S., Soysal S.D., Gao F., Obermann E.C., Oertli D., GillandersW.E.: The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis inhuman breast cancer. Breast Cancer Res. Treat., 2013; 139: 667-676
  Google Scholar
• 43. Ngiow S.F., Teng M.W., Smyth M.J.: Prospects for TIM3-targetedantitumor immunotherapy. Cancer Res., 2011; 71: 6567-6571
  Google Scholar
• 44. Ngiow S.F., von Scheidt B., Akiba H., Yagita H., Teng M.W., SmythM.J.: Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumorimmunity and suppresses established tumors. Cancer Res., 2011;71: 3540-3551
  Google Scholar
• 45. O’Day S.J., Maio M., Chiarion-Sileni V., Gajewski T.F., PehambergerH., Bondarenko I.N., Queirolo P., Lundgren L., Mikhailov S.,Roman L., Verschraegen C., Humphrey R., Ibrahim R., de Pril V., HoosA., Wolchok J.D.: Efficacy and safety of ipilimumab monotherapy inpatients with pretreated advanced melanoma: a multicenter singlearmphase II study. Ann. Oncol., 2010; 21: 1712-1717
  Google Scholar
• 46. Pardoll D.M.: The blockade of immune checkpoints in cancerimmunotherapy. Nat. Rev. Cancer, 2012; 12: 252-264
  Google Scholar
• 47. Pardoll D.M., Drake C.: Immunotherapy earns its spot in theranks of cancer therapy. J. Exp. Med., 2012; 209: 201-209
  Google Scholar
• 48. Parsa A.T., Waldron J.S., Panner A., Crane C.A., Parney I.F., BarryJ.J., Cachola K.E., Murray J.C., Tihan T., Jensen M.C., Mischel P.S.,Stokoe D., Pieper R.O.: Loss of tumor suppressor PTEN function increasesB7-H1 expression and immunoresistance in glioma. Nat.Med., 2007;. 13: 84-88
  Google Scholar
• 49. Pasero C., Olive D.: Interfering with coinhibitory molecules:BTLA/HVEM as new targets to enhance anti-tumor immunity. Immunol.Lett., 2013; 151: 71-75
  Google Scholar
• 50. Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K.,McDermott D., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S.,Shaheen M., Ernstoff M.S., Minor D., Salama A.K., Taylor M. i wsp.:Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N. Engl. J. Med., 2015; 21: 2006-2017
  Google Scholar
• 51. Postow M.A., Yuan J., Kitano S., Lesokhin A.M., Wolchok J.D.:Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA – 4) therapyin melanoma. Methods Mol. Biol., 2014; 1102: 83-95
  Google Scholar
• 52. Powles T., Eder J.P., Fine G.D., Braiteh F.S., Loriot Y., Cruz C., BellmuntJ., Burris H.A., Petrylak D.P., Teng S.L., Shen X., Boyd Z., Hegde P.S.,Chen D.S.,Vogelzang N.J.: MPDL3280A (anti-PD-L1) treatment leads toclinical activity in metastatic bladder cancer. Nature, 2014; 515: 558-562
  Google Scholar
• 53. Press Announcements > FDA approves Keytruda for advancedmelanoma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm (29.12.2014)
  Google Scholar
• 54. Press Announcements > FDA approves Opdivo for advancedmelanoma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427716.htm (29.12.2014)
  Google Scholar
• 55. Press Announcements > FDA expands approved use of Opdivoto treat lung cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436534.htm (09.05.2015)
  Google Scholar
• 56. Qian Y., Hong B., Shen L., Wu Z., Yao H., Zhang L.: B7-H4 enhancesoncogenicity and inhibits apoptosis in pancreatic cancer cells. Cell.Tissue. Res., 2013; 353: 139-151
  Google Scholar
• 57. Ribas A.: Clinical development of the anti-CTLA-4 antibodytremelimumab. Semin. Oncol., 2010; 37: 450-454
  Google Scholar
• 58. Ribas A., Kefford R., Marshall M.A., Punt C.J., Haanen J.B., MarmolM., Garbe C., Gogas H., Schachter J., Linette G., Lorigan P., Kendra K.L.,Maio M., Trefzer U., Smylie M. i wsp.: Phase III randomized clinicaltrial comparing tremelimumab with standard-of-care chemotherapyin patients with advanced melanoma. J. Clin. Oncol., 2013; 31: 616-622
  Google Scholar
• 59. Riella L.V., Peterson A.M., Sharpe A.H., Chandraker A.: Role ofthe PD-1 pathway in the immune response. Am. J. Transplant., 2012;12: 2575-2587
  Google Scholar
• 60. Riley J.L.: PD-1 signaling in primary T cells. Immunol. Rev., 2009;229: 114-125
  Google Scholar
• 61. Rizvi N.A., Mazières J., Planchard D., Stinchcombe T.E., Dy G.K.,Antonia S.J., Horn L., Lena H., Minenza E., Mennecier B., OttersonG.A., Campos L.T., Gandara D.R., Levy B.P., Nair S.G. i wsp.: Activityand safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor,for patients with advanced, refractory squamous non-small-celllung cancer (CheckMate 063): a phase 2, single-arm trial. LancetOncol., 2015; 16: 257-265
  Google Scholar
• 62. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L.,Hassel J.C., Rutkowski P., McNeil C., Kalinka-Warzocha E., Savage K.J.,Hernberg M.M., Lebbé C., Charles J., Mihalcioiu C. i wsp.: Nivolumabin previously untreated melanoma without BRAF mutation. N. Engl.J. Med., 2015; 372: 320-330
  Google Scholar
• 63. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R.,Weber J.S., Joshua A.M., Hwu W.J., Gangadhar T.C., Patnaik A., DroncaR., Zarour H., Joseph R.W., Boasberg P. i wsp.: Anti-programmeddeath-receptor-1 treatment with pembrolizumab in ipilimumabrefractoryadvanced melanoma: a randomised dose-comparisoncohort of a phase 1 trial. Lancet, 2014; 384: 1109-1117
  Google Scholar
• 64. Robert C., Schachter J., Long G.V., Arance A., Grob J.J., MortierL., Daud A., Carlino M.S., McNeil C., Lotem M., Larkin J., Lorigan P.,Neyns B., Blank C.U., Hamid O. i wsp.: Pembrolizumab versus Ipilimumabin Advanced Melanoma. N. Eng. J. Med., 2015; 372: 2521-2532
  Google Scholar
• 65. Robert C., Thomas L., Bondarenko I., O’Day S., Weber J., GarbeC., Lebbe C., Baurain J.F., Testori A., Grob J.J., Davidson N., RichardsJ., Maio M., Hauschild A., Miller W.H. Jr i wsp.: Ipilimumab plus decarbazinefor previously untreated metastatic melanoma. N. Engl.J. Med., 2011; 364: 2517-2526
  Google Scholar
• 66. Rosenwald A., Wright G., Leroy K., Yu X., Gaulard P., GascoyneR.D., Chan W.C., Zhao T., Haioun C., Greiner T.C., Weisenburger D.D.,Lynch J.C., Vose J., Armitage J.O., Smeland E.B. i wsp.: Molecular diagnosisof primary mediastinal B cell lymphoma identifies a clinicallyfavorable subgroup of diffuse large B cell lymphoma related toHodgkin lymphoma. J. Exp. Med., 2003; 198: 851-862
  Google Scholar
• 67. Slovin S.F., Higano C.S., Hamid O., Tejwani S., Harzstark A., AlumkalJ.J., Scher H.I., Chin K., Gagnier P., McHenry M.B., Beer T.M.: Ipilimumabalone or in combination with radiotherapy in metastaticcastration-resistant prostate cancer: results from an open-label,multicenter phase I/II study. Ann. Oncol., 2013; 24: 1813-1821
  Google Scholar
• 68. Sznol M., Chen L.: Antagonist antibodies to PD-1 and B7-H1(PD-L1) in the treatment of advanced human cancer. Clin. Cancer.Res., 2013; 19: 1021-1034
  Google Scholar
• 69. Tai X., Van Laethem F., Pobezinsky L., Guinter T., Sharrow S.O.,Adams A., Granger L., Kruhlak M., Lindsten T., Thompson C.B., FeigenbaumL., Singer A.: Basis of CTLA-4 function in regulatory andconventional CD4(+) T cells. Blood, 2012; 119: 5155-5163
  Google Scholar
• 70. Taube J.M., Anders R.A., Young G.D., Xu H., Sharma R., McMillerT.L., Chen S., Klein A.P., Pardoll D.M., Topalian S.L., Chen L.: Colocalizationof inflammatory response with B7-H1 expression in humanmelanocytic lesions supports an adaptive resistance mechanism ofimmune escape. Sci. Transl. Med., 2012; 4: 127-137
  Google Scholar
• 71. Taube J.M., Klein A., Brahmer J.R., Xu H., Pan X., Kim J.H., ChenL., Pardoll D.M., Topalian S.L., Anders R.A.: Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer. Res., 2014;20: 5064-5074
  Google Scholar
• 72. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C.,McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., AtkinsM.B., Leming P.D., Spigel D.R., Antonia S.J., Horn L., Drake C.G. i wsp.:Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N. Engl. J. Med., 2012; 366: 2443-2454
  Google Scholar
• 73. Topalian S.L., Sznol M., McDermott D.F., Kluger H.M., CarvajalR.D., Sharfman W.H., Brahmer J.R., Lawrence D.P., Atkins M.B., PowderlyJ.D., Leming P.D., Lipson E.J., Puzanov I., Smith D.C., Taube J.M.i wsp.: Survival, durable tumor remission, and long term safety inpatients with advanced melanoma with nivolumab. J. Clin. Oncol.,2014; 32: 1020-1030
  Google Scholar
• 74. Topalian S.L., Weiner G.J., Pardoll D.N.: Cancer immunotherapycomes of age. J. Clin. Oncol., 2011; 29: 4828-4836
  Google Scholar
• 75. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J.,Robert L., Chmielowski B., Spasic M., Henry G., Ciobanu V., WestA.N., Carmona M., Kivork C., Seja E., Cherry G. i wsp.: PD-1 blockadeinduces responses by inhibiting adaptive immune resistance. Nature,2014; 515: 568-571
  Google Scholar
• 76. van Elsas A., Hurwitz A.A., Allison J.P.: Combination immunotherapyof B16 melanoma using anti-cytotoxic T lymphocyte-associatedantigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulatingfactor (GM-CSF)-producing vaccines induces rejection ofsubcutaneous and metastatic tumors accompanied by autoimmunedepigmentation. J. Exp. Med., 1999; 190: 355-366
  Google Scholar
• 77. Wada S., Jackson C.M., Yoshimura K., Yen H.R., Getnet D., HarrisT.J., Goldberg M.V., Bruno T.C., Grosso J.F., Durham N., Netto G.J.,Pardoll D.M., Drake C.G.: Sequencing CTLA-4 blockade with cell-basedimmunotherapy for prostate cancer. J. Transl. Med., 2013; 11: 89
  Google Scholar
• 78. Wang J., Chong K.K., Nakamura Y., Nguyen L., Huang S.K., KuoC., Zhang W., Yu H., Morton D.L., Hoon D.S.: B7-H3 associated withtumor progression and epigenetic regulatory activity in cutaneousmelanoma. J. Invest. Dermatol. 2013; 133: 2050-2058
  Google Scholar
• 79. Weber J.S., D’Angelo S.P., Minor D., Hodi F.S., Gutzmer R., NeynsB., Hoeller C., Khushalani N.I., Miller W.H.Jr., Lao C.D., Linette G.P.,Thomas L., Lorigan P., Grossmann K.F., Hassel J.C. i wsp.: Nivolumabversus chemotherapy in patients with advanced melanoma who progressedafter anti-CTLA-4 treatment (CheckMate 037): a randomised,controlled, open-label, phase 3 trial. Lancet Oncol., 2015; 16: 375-384
  Google Scholar
• 80. Weber J., Hamid O., Amin A., O’Day S., Masson E., Goldberg S.M.,Williams D., Parker S.M., Chasalow S.D., Alaparthy S., Wolchok J.D.:Randomized phase I pharmacokinetic study of ipilimumab with orwithout one of two different chemotherapy regimens in patientswith untreated advanced melanoma. Cancer Immun., 2013; 13: 7-15
  Google Scholar
• 81. Weber J.S., Kahler K.C., Hauschild A.: Management of immune–related adverse events and kinetics of response with ipilimumab.J. Clin. Oncol., 2012; 30: 2691-2697
  Google Scholar
• 82. Wolchok J.D., Hodi S.F., Weber J.S., Allison J.P., Urba W.J., RobertC., O’Day S.J., Hoos A., Humphrey R., Berman D.M., Lonberg N., KormanA.J.: Development of ipilimumab: a novel immunotherapeuticapproach for the treatment of advanced melanoma. Ann. N. Y. Acad.Sci., 2013; 1291: 1-13
  Google Scholar
• 83. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A.,Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., BurkeM.M., Caldwell A., Kronenberg S.A., Agunwamba B.U., Zhang X.i wsp.: Nivolumab plus ipilimumab in advanced melanoma. N. Engl.J. Med., 2013; 369: 122-133
  Google Scholar
• 84. Wolchok J.D., Neyns B., Linette G., Negrier S., Lutzky J., ThomasL., Waterfield W., Schadendorf D., Smylie M., Guthrie T. Jr., Grob J.J.,Chesney J., Chin K., Chen K., Hoos A. i wsp.: Ipilimumab monotherapyin patients with pretreated advanced melanoma: a randomised,double-blind, multicentre, phase 2, dose-ranging study. LancetOncol., 2010; 11: 155-164
  Google Scholar
• 85. Wolchok J.D., Weber J.S., Maio M., Neyns B., Harmankaya K.,Chin K., Cykowski L., de Pril V., Humphrey R., Lebbé C.: Four-yearsurvival rates for patients with metastatic melanoma who receivedipilimumab in phase II clinical trials. Ann. Oncol., 2013; 24:2174-2180
  Google Scholar
• 86. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M.,Nirschl C.J., Bettini M.L., Gravano D.M., Vogel P., Liu C.L., TangsombatvisitS., Grosso J.F., Netto G., Smeltzer M.P., Chaux A. i wsp.:Immune inhibitory molecules LAG-3 and PD-1 synergistically regulateT-cell function to promote tumoral immune escape. CancerRes., 2012; 72: 917-927
  Google Scholar
• 87. Wu L., Yun Z., Tagawa T., Rey-McIntyre K., de Perrot M.: CTLA-4blockade expands infiltrating T cells and inhibits cancer cell repopulationduring the intervals of chemotherapy in murine mesothelioma.Mol. Cancer. Ther., 2012; 11: 1809-1819
  Google Scholar
• 88. Yao S., Chen L.: Adaptive resistance: A tumor strategy to evadeimmune attack. Eur. J. Immunol., 2013; 43: 576-579
  Google Scholar
• 89. Zeng J., See A.P., Phallen J., Jackson C.M., Belcaid Z., RuzevickJ., Durham N., Meyer C., Harris T.J., Albesiano E., Pradilla G., Ford E.,Wong J., Hammers H.J., Mathios D. i wsp.: Anti-PD-1 blockade andstereotactic radiation produce long-term survival in mice with intracranialgliomas. Int. J. Radiat. Oncol. Biol. Phys., 2013; 86: 343-349
  Google Scholar
• 90. Zhou Q., Munger M.E., Highfill S.L., Tolar J., Weigel B.J., Riddle M.,Sharpe A.H., Vallera D.A., Azuma M., Levine B.L., June C.H., MurphyW.J., Munn D.H., Blazar B.R.: Program death-1 signaling and regulatoryT cells collaborate to resist the function of adoptively transferredcytotoxic T lymphocytes in advanced acute myeloid leukemia.Blood, 2010; 116: 2484-2493
  Google Scholar
• 91. Zou W., Chen L.: Inhibitory B7-family molecules in the tumourmicroenvironment. Nat. Rev. Immunol., 2008; 8: 467-477
  Google Scholar

Full text